Quantbot Technologies LP Takes $12.19 Million Position in Insulet Corporation $PODD

Quantbot Technologies LP bought a new stake in Insulet Corporation (NASDAQ:PODD) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 38,812 shares of the medical instruments supplier’s stock, valued at approximately $12,194,000. Quantbot Technologies LP owned 0.06% of Insulet as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of PODD. Zions Bancorporation National Association UT bought a new stake in Insulet in the first quarter valued at approximately $26,000. Golden State Wealth Management LLC increased its holdings in shares of Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 69 shares during the last quarter. SouthState Corp raised its stake in Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 76 shares during the period. Kozak & Associates Inc. bought a new stake in Insulet in the 2nd quarter valued at $32,000. Finally, Trust Co. of Toledo NA OH acquired a new stake in Insulet during the 2nd quarter valued at $35,000.

Wall Street Analysts Forecast Growth

Several research firms have commented on PODD. Oppenheimer upped their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a report on Monday, September 8th. Raymond James Financial upped their price target on shares of Insulet from $366.00 to $385.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Wolfe Research raised their price objective on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Royal Bank Of Canada boosted their price objective on Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Finally, Canaccord Genuity Group increased their target price on Insulet from $428.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $379.65.

Insider Transactions at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.39% of the company’s stock.

Insulet Trading Down 5.0%

Shares of PODD stock opened at $310.83 on Tuesday. The stock has a market cap of $21.87 billion, a P/E ratio of 94.48, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock has a 50 day simple moving average of $321.49 and a 200 day simple moving average of $316.25.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company’s quarterly revenue was up 29.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.